Multiplex Assay Kit for Thrombin/Antithrombin Complex (TAT) ,etc. by FLIA (Flow Luminescence Immunoassay) 
(Note: Up to 8-plex in one testing reaction)
- UOM
- FOB US$ 405.00 US$ 420.00 US$ 443.00 US$ 475.00 US$ 506.00 US$ 552.00 US$ 622.00 US$ 778.00
- Quantity
Overview
Properties
- Product No.LMA831Mu
- Organism SpeciesMus musculus (Mouse) Same name, Different species.
- ApplicationsFLIA Kit for Antigen Detection.
Research use only - DownloadInstruction Manual
- CategorySignal transductionEnzyme & KinaseMetabolic pathwayHematology
Sign into your account
Share a new citation as an author
Upload your experimental result
Review
Contact us
Please fill in the blank.
-
Packages (Simulation)
-
Packages (Simulation)
-
Results demonstration
-
Typical Standard Curve
-
ISO9001: 2008, ISO13485: 2003 Registered
Recovery
Matrices listed below were spiked with certain level of recombinant Thrombin/Antithrombin Complex (TAT) ,etc. by FLIA (Flow Luminescence Immunoassay) and the recovery rates were calculated by comparing the measured value to the expected amount of Thrombin/Antithrombin Complex (TAT) ,etc. by FLIA (Flow Luminescence Immunoassay) in samples.
| Matrix | Recovery range (%) | Average(%) |
| serum(n=5) | 79-88 | 85 |
| EDTA plasma(n=5) | 81-102 | 98 |
| heparin plasma(n=5) | 91-99 | 95 |
Precision
Intra-assay Precision (Precision within an assay): 3 samples with low, middle and high level Thrombin/Antithrombin Complex (TAT) ,etc. by FLIA (Flow Luminescence Immunoassay) were tested 20 times on one plate, respectively.
Inter-assay Precision (Precision between assays): 3 samples with low, middle and high level Thrombin/Antithrombin Complex (TAT) ,etc. by FLIA (Flow Luminescence Immunoassay) were tested on 3 different plates, 8 replicates in each plate.
CV(%) = SD/meanX100
Intra-Assay: CV<10%
Inter-Assay: CV<12%
Linearity
The linearity of the kit was assayed by testing samples spiked with appropriate concentration of Thrombin/Antithrombin Complex (TAT) ,etc. by FLIA (Flow Luminescence Immunoassay) and their serial dilutions. The results were demonstrated by the percentage of calculated concentration to the expected.
| Sample | 1:2 | 1:4 | 1:8 | 1:16 |
| serum(n=5) | 91-104% | 81-94% | 91-105% | 92-101% |
| EDTA plasma(n=5) | 78-102% | 91-102% | 78-101% | 97-105% |
| heparin plasma(n=5) | 97-105% | 87-94% | 98-105% | 83-104% |
Stability
The stability of kit is determined by the loss rate of activity. The loss rate of this kit is less than 5% within the expiration date under appropriate storage condition.
To minimize extra influence on the performance, operation procedures and lab conditions, especially room temperature, air humidity, incubator temperature should be strictly controlled. It is also strongly suggested that the whole assay is performed by the same operator from the beginning to the end.
Reagents and materials provided
| Reagents | Quantity | Reagents | Quantity |
| 96-well plate | 1 | Plate sealer for 96 wells | 4 |
| Pre-Mixed Standard | 2 | Standard Diluent | 1×20mL |
| Pre-Mixed Magnetic beads (22#:TAT) | 1 | Analysis buffer | 1×20mL |
| Pre-Mixed Detection Reagent A | 1×120μL | Assay Diluent A | 1×12mL |
| Detection Reagent B (PE-SA) | 1×120μL | Assay Diluent B | 1×12mL |
| Sheath Fluid | 1×10mL | Wash Buffer (30 × concentrate) | 1×20mL |
| Instruction manual | 1 |
Assay procedure summary
1. Preparation of standards, reagents and samples before the experiment;
2. Add 100μL standard or sample to each well,
add 10μL magnetic beads, and incubate 90min at 37°C on shaker;
3. Remove liquid on magnetic frame, add 100μL prepared Detection Reagent A. Incubate 60min at 37°C on shaker;
4. Wash plate on magnetic frame for three times;
5. Add 100μL prepared Detection Reagent B, and incubate 30 min at 37°C on shaker;
6. Wash plate on magnetic frame for three times;
7. Add 100μL sheath solution, swirl for 2 minutes, read on the machine.
Test principle
Analyte-specific antibodies are pre-coated onto color-coded microparticles. Microparticles, standards, and samples are pipetted into wells and the immobilized antibodies bind the analytes of interest. After washing away any unbound substances, a biotinylated antibody cocktail specific to the analytes of interest is added to each well. Following a wash to remove any unbound biotinylated antibody, Streptavidin-Phycoerythrin conjugate (Streptavidin-PE), which binds to the biotinylated detection antibodies, is added to each well. A final wash removes unbound Streptavidin-PE and the microparticles are resuspended in buffer and read using the Luminex or Bio-Plex analyzer.The MFI developed is proportional to the concentration of analytes of interest in the sample.
Giveaways
Increment services
Citations
- Genetic repression of mouse VEGF expression regulates coagulation cascade.PubMed: 21086498
- Treatment with unfractionated heparin attenuates coagulation and inflammation in endotoxemic miceScienceDirect: S0049384811004166
- High sCD40L levels early after trauma are associated with enhanced shock, sympathoadrenal activation, tissue and endothelial damage, coagulopathy and mortalityWiley: source
- Tissue factor and PAR1 promote microbiota-induced intestinal vascular remodellingNature: 20120329
- Prolonged Exposure to Sphingosine 1–Phosphate Receptor-1 Agonists Exacerbates Vascular Leak, Fibrosis, and Mortality after Lung InjuryPubMed: PMC2993087
- Host Defense Peptides of Thrombin Modulate Inflammation and Coagulation in Endotoxin-Mediated Shock and Pseudomonas aeruginosa SepsisPubMed: PMC3521733
- Clinical impact of factor V Leiden, prothrombin G20210A, and MTHFR C677T mutations among sickle cell disease patients of Central IndiaPubmed: 23992124
- Selected hemostatic parameters in patients with pancreatic tumors.Pubmed:Pmc4297344
- TFPI1 Mediates Resistance to Doxorubicin in Breast Cancer Cells by Inducing a Hypoxic-Like ResponsePubmed:24489651
- Novel evidence that crosstalk between the complement, coagulation and fibrinolysis proteolytic cascades is involved in mobilization of hematopoietic stem/progenitor cells (HSPCs)Pubmed:24667943
- Thrombomodulin Improved Liver Injury, Coagulopathy, and Mortality in an Experimental Heatstroke Model in MicePubmed:24781566
- Evidence of a Pivotal Role for the Distal Part of the Complement Cascade in the Diurnal Release of Hematopoietic Stem Cells Into Peripheral BloodPubmed:26087465
- (S)YS-51, a novel isoquinoline alkaloid, attenuates obesity-associated non-alcoholic fatty liver disease in mice by suppressing lipogenesis, inflammation and coaCavia (Guinea pig )lationPubmed:27343380
- Coagulation factor XI vaccination: an alternative strategy to prevent thrombosis.pubmed:27813324
- Nebulized Heparin Attenuates Pulmonary Coagulopathy and Inflammation through Alveolar Macrophages in a Rat Model of Acute Lung Injurypubmed:29202212
- Platelet-localized FXI promotes a vascular coagulation-inflammatory circuit in arterial hypertensionpubmed:28148841
- Activated TAFI Promotes the Development of Chronic Thromboembolic Pulmonary Hypertension: A Possible Novel Therapeutic Targetpubmed:28289017
- Nebulized anti-coagulants as a therapy for acute lung injury and acute respiratory distress syndromePubmed: 29202212
- The circadian rhythm of selected parameters of the hemostasis system in healthy people
- Transduced Tat-aldose Reductase Protects Hippocampal Neuronal Cells against Oxidative Stress-induced DamagePubmed: 31698553
- The impact of dabigatran treatment on sinusoidal protection against hepatic ischemia‐reperfusion injury in micePubmed: 33108682
- Doxorubicin contributes to thrombus formation and vascular injury via enhancing platelet functions in vivoPubmed: 32469636
- Preservation of renal endothelial integrity and reduction of renal edema by aprotinin does not preserve renal perfusion and function following experimental …34169407
- Complement factor D is linked to platelet activation in human and rodent sepsis34396466